Problems With Drug Absorption Studies Still ‘Relatively Common’ In EU
Inadequacies Have Drawn Major Objections During Initial EMA Review
Executive Summary
A retrospective analysis of new drugs evaluated by the European Medicines Agency since 2010 shows that a lack of, or major deficiencies in, human mass balance studies is still a concern in regulatory submissions.
You may also be interested in...
Ambitious AB Science Gets Masitinib Win For Severe Asthma
Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes masitinib could be effective for ALS, multiple sclerosis, cancers, asthma and even Alzheimer's.
Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
Patient Voice Makes Impact In Scientific Advice From EU HTA Network
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: